Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,497
  • Shares Outstanding, K 58,888
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,790 K
  • 60-Month Beta 1.28
  • Price/Sales 8.48
  • Price/Cash Flow N/A
  • Price/Book 0.95
Trade PYXS with:

Options Overview Details

View History
  • Implied Volatility 10.70% ( +10.70%)
  • Historical Volatility 57.45%
  • IV Percentile 2%
  • IV Rank 0.00%
  • IV High 656.63% on 12/27/23
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 5,255
  • Open Int (30-Day) 4,823

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.35
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +13.88%
on 07/09/24
3.90 -18.05%
on 06/17/24
-0.59 (-15.57%)
since 06/14/24
3-Month
2.81 +13.88%
on 07/09/24
5.09 -37.13%
on 04/17/24
-1.54 (-32.49%)
since 04/15/24
52-Week
1.35 +137.04%
on 11/24/23
6.85 -53.28%
on 02/27/24
+0.55 (+20.75%)
since 07/14/23

Most Recent Stories

More News
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 1.0800 (+3.85%)
ONC.TO : 1.49 (+3.47%)
PYXS : 3.20 (+1.59%)
AZN : 78.12 (-1.41%)
LLY : 950.46 (+0.22%)
MRUS : 58.10 (+1.47%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.49 (+3.47%)
ONCY : 1.0800 (+3.85%)
PYXS : 3.20 (+1.59%)
AZN : 78.12 (-1.41%)
LLY : 950.46 (+0.22%)
MRUS : 58.10 (+1.47%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 1.0800 (+3.85%)
ONC.TO : 1.49 (+3.47%)
PYXS : 3.20 (+1.59%)
AZN : 78.12 (-1.41%)
LLY : 950.46 (+0.22%)
MRUS : 58.10 (+1.47%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 3.20 (+1.59%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 3.20 (+1.59%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...

PYXS : 3.20 (+1.59%)
NIRI Chicago Elects 2022-2023 Officers and Directors

The Chicago Chapter of the National Investor Relations Institute (NIRI Chicago) has elected 12 officers and directors to its board for the 2022-2023 term, effective July 1.

UNVR : 36.14 (+0.47%)
WEBR : 8.12 (unch)
PTLO : 9.54 (+0.53%)
MEI : 13.65 (-1.09%)
ACCO : 4.74 (+1.28%)
ZBRA : 327.50 (+0.71%)
BY : 26.10 (+3.16%)
GCMG : 10.50 (+1.25%)
HZNP : 116.30 (+0.04%)
CF : 70.75 (+0.16%)
CTSO : 1.0700 (-0.93%)
PYXS : 3.20 (+1.59%)
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...

PYXS : 3.20 (+1.59%)
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing...

PYXS : 3.20 (+1.59%)
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing...

PYXS : 3.20 (+1.59%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.37
2nd Resistance Point 3.33
1st Resistance Point 3.26
Last Price 3.20
1st Support Level 3.15
2nd Support Level 3.11
3rd Support Level 3.04

See More

52-Week High 6.85
Fibonacci 61.8% 4.75
Fibonacci 50% 4.10
Fibonacci 38.2% 3.45
Last Price 3.20
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar